Experiment Overview
| Repository ID: | FR-FCM-Z76E | Experiment name: | MCP_MassCytometry_ADHM2024 | MIFlowCyt score: | 15.00% |
| Primary researcher: | Sarwish Rafiq | PI/manager: | Sarwish Rafiq | Uploaded by: | Sarwish Rafiq |
| Experiment dates: | 2024-01-31 - | Dataset uploaded: | Jan 2024 | Last updated: | Jan 2024 |
| Keywords: | None | Manuscripts: | [38245855] | ||
| Organizations: | None | ||||
| Purpose: | Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieves a durable complete response (dCR). DCR has been correlated with CAR T cell products enriched with T cell memory phenotypes. Therefore, reagents that consistently promote memory phenotypes during the manufacturing of CAR T cells have the potential to significantly improve clinical outcomes. A novel modular multi-cytokine particle (MCP) platform is developed that combines the signals necessary for activation, costimulation, and cytokine support into a single ?all-in-one? stimulation reagent for CAR T cell manufacturing. This platform allows for the assembly and screening of compositionally diverse MCP libraries to identify formulations tailored to promote specific phenotypes with a high degree of flexibility. This platform is leveraged to identify unique MCP formulations that manufacture CAR T cells that exhibit increased proportions of memory-like phenotypes in diffuse large B cell lymphoma (DLBCL) patient CAR T cells and demonstrate superior anti-tumor efficacy in mouse models of lymphoma and ovarian cancer through enhanced persistence. These findings serve as a proof-of-principle of the powerful utility of the MCP platform to identify ?all-in-one? stimulation reagents that can improve the effectiveness of cell therapy products through optimal manufacturing. | ||||
| Conclusion: | None | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | None | ||||
